BIOMAT Database Logo BIOMAT Database Logo

Induction of eruptive benign melanocytic naevi by immune suppressive agents, including biologicals. 2006

H J Bovenschen, and M Tjioe, and H Vermaat, and D de Hoop, and B M J Witteman, and R W A Janssens, and T J Stoof, and P C M van de Kerkhof
Department of Dermatology, Radboud University Nijmegen Medical Centre, and Department of Gastroenterology, Gelderse Vallei Hospital, Ede, the Netherlands. j.bovenschen@derma.umcn.nl

BACKGROUND Eruptive naevi have been described to potentially arise in immune compromised patients. OBJECTIVE We describe three patients with eruptive benign melanocytic naevi during a phase of immunosuppressive therapy. METHODS/DIAGNOSIS: Two patients with Crohn disease were treated with either azathioprine monotherapy or a combination of azathioprine and infliximab, when eruptive naevi arose particularly at the palms and soles. Our third patient with plaque psoriasis developed eruptive naevi during two episodes of treatment: during a course with the biological agent alefacept and during etanercept therapy. CONCLUSIONS We conclude that treatment with the recently available biological agents might be associated with the formation of eruptive naevi. Although positive evidence for the occurrence of malignant pigmented lesions is lacking, alertness to the development of eruptive melanocytic naevi during treatment with biological agents is indicated.

UI MeSH Term Description Entries
D007155 Immunologic Factors Biologically active substances whose activities affect or play a role in the functioning of the immune system. Biological Response Modifier,Biomodulator,Immune Factor,Immunological Factor,Immunomodulator,Immunomodulators,Biological Response Modifiers,Biomodulators,Factors, Immunologic,Immune Factors,Immunological Factors,Modifiers, Biological Response,Response Modifiers, Biological,Factor, Immune,Factor, Immunological,Factors, Immune,Factors, Immunological,Modifier, Biological Response,Response Modifier, Biological
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009508 Nevus, Pigmented A nevus containing melanin. The term is usually restricted to nevocytic nevi (round or oval collections of melanin-containing nevus cells occurring at the dermoepidermal junction of the skin or in the dermis proper) or moles, but may be applied to other pigmented nevi. Nevus, Melanocytic,Nevi, Melanocytic,Nevi, Pigmented,Pigmented Moles,Melanocytic Nevi,Melanocytic Nevus,Pigmented Nevi,Pigmented Nevus
D003875 Drug Eruptions Adverse cutaneous reactions caused by ingestion, parenteral use, or local application of a drug. These may assume various morphologic patterns and produce various types of lesions. Dermatitis Medicamentosa,Dermatitis, Adverse Drug Reaction,Maculopapular Drug Eruption,Maculopapular Exanthem,Morbilliform Drug Reaction,Morbilliform Exanthem,Drug Eruption,Drug Eruption, Maculopapular,Drug Eruptions, Maculopapular,Drug Reaction, Morbilliform,Drug Reactions, Morbilliform,Eruption, Drug,Eruption, Maculopapular Drug,Eruptions, Drug,Eruptions, Maculopapular Drug,Exanthem, Maculopapular,Exanthem, Morbilliform,Exanthems, Maculopapular,Exanthems, Morbilliform,Maculopapular Drug Eruptions,Maculopapular Exanthems,Morbilliform Drug Reactions,Morbilliform Exanthems,Reaction, Morbilliform Drug,Reactions, Morbilliform Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001379 Azathioprine An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed) Azathioprine Sodium,Azathioprine Sodium Salt,Azathioprine Sulfate,Azothioprine,Immuran,Imuran,Imurel,Sodium, Azathioprine

Related Publications

H J Bovenschen, and M Tjioe, and H Vermaat, and D de Hoop, and B M J Witteman, and R W A Janssens, and T J Stoof, and P C M van de Kerkhof
Eruptive melanocytic naevi following melanotan injection.
September 2009, The British journal of dermatology,
H J Bovenschen, and M Tjioe, and H Vermaat, and D de Hoop, and B M J Witteman, and R W A Janssens, and T J Stoof, and P C M van de Kerkhof
Eruptive benign melanocytic naevi during immunosuppressive therapy in a Crohn's disease patient.
June 2011, Inflammatory bowel diseases,
H J Bovenschen, and M Tjioe, and H Vermaat, and D de Hoop, and B M J Witteman, and R W A Janssens, and T J Stoof, and P C M van de Kerkhof
Excess benign melanocytic naevi.
September 1989, BMJ (Clinical research ed.),
H J Bovenschen, and M Tjioe, and H Vermaat, and D de Hoop, and B M J Witteman, and R W A Janssens, and T J Stoof, and P C M van de Kerkhof
Eruptive melanocytic naevi following severe bullous disease.
November 1978, The British journal of dermatology,
H J Bovenschen, and M Tjioe, and H Vermaat, and D de Hoop, and B M J Witteman, and R W A Janssens, and T J Stoof, and P C M van de Kerkhof
Activating BRAF mutations in eruptive melanocytic naevi.
November 2010, The British journal of dermatology,
H J Bovenschen, and M Tjioe, and H Vermaat, and D de Hoop, and B M J Witteman, and R W A Janssens, and T J Stoof, and P C M van de Kerkhof
Eruptive melanocytic naevi as a sign of primary adrenocortical insufficiency.
December 2013, Clinical and experimental dermatology,
H J Bovenschen, and M Tjioe, and H Vermaat, and D de Hoop, and B M J Witteman, and R W A Janssens, and T J Stoof, and P C M van de Kerkhof
Atypical dermal nodules in benign melanocytic naevi.
July 1997, Histopathology,
H J Bovenschen, and M Tjioe, and H Vermaat, and D de Hoop, and B M J Witteman, and R W A Janssens, and T J Stoof, and P C M van de Kerkhof
Admixed desmoplastic trichoepithelioma and benign melanocytic naevi.
March 2008, Journal of the European Academy of Dermatology and Venereology : JEADV,
H J Bovenschen, and M Tjioe, and H Vermaat, and D de Hoop, and B M J Witteman, and R W A Janssens, and T J Stoof, and P C M van de Kerkhof
Eruptive melanocytic naevi provoked by sunbed use in a patient on systemic immunosuppression.
March 2020, Clinical and experimental dermatology,
H J Bovenschen, and M Tjioe, and H Vermaat, and D de Hoop, and B M J Witteman, and R W A Janssens, and T J Stoof, and P C M van de Kerkhof
Massively parallel sequencing analysis of benign melanocytic naevi.
July 2019, Histopathology,
Copied contents to your clipboard!